Leadership Perspectives
Welcome to the Janssen Oncology ASCO GU Virtual Newsroom
At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are driven by our vision to eliminate cancer. As we pursue this ambitious goal, we are pleased to share data that reinforce the promise of our prostate cancer pipeline and portfolio at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium for the ninth consecutive year. Building on our long-term leadership in prostate cancer, Janssen is committed to advancing innovative treatments and transforming patient experiences while focusing on research that may drive better outcomes for people with genitourinary cancers.
Janssen has 17 presentations featured that will highlight compelling new data from approved and investigational products, and novel approaches in prostate and bladder cancer. By continuing to advance the understanding of prostate cancer, we aim to expand options for patients and grow the body of evidence for existing medicines to support patients on their path to better care.
We look forward to this important scientific exchange that is integral to developing new therapeutic options for patients and those who care for them. Thank you for visiting Janssen's ASCO GU 2022 Virtual Newsroom to learn more about our latest research.
Kiran Patel, M.D.
Vice President
Clinical Development, Solid Tumors
Janssen Research & Development, LLC
Rodney Gillespie
Vice President
Oncology Sales & Marketing, Solid Tumor
Janssen Biotech, Inc.
Chumi Khurana, Vice President, Global Commercial Leader, Prostate Cancer, and Chris Cutie, Vice President, Disease Area Leader, Bladder Cancer, share their perspectives on data at ASCO GU.